The therapy of nanoparticles may be effective for the treatment of acute myeloid leukemia

A study published this week in the journal Nature - communication indicated that nanoparticles carrying a class of non-code RNA small molecule miR-22 which can regulate gene expression shows the therapeutic potential of mice model with acute myeloid leukemia.

Acute myeloid leukemia is a cancer of blood cells, and it will still take away people's lives in five years even after intensive chemotherapy. While we have a lot of information about the characteristics of acute myelogenous leukemia genomic variation, the drive progenitor cells into cancer cells, the molecular mechanisms that we know very little.

Chen Jianjun and his research team analyzed 62 samples of cancer patients and found that individual class in acute myeloid leukemia express miR-22 is reduced. Using a variety of mouse models of acute myeloid leukemia, the study indicates that the recovery of the expression level of miR-22 can inhibit specific cellular pathway, hinder the development of acute myeloid leukemia and cancer cells is maintained. Researchers followed by nanoparticle transport miR-22 short-chain RNA into two kinds of leukemia mouse model, a mouse leukemia cells containing GM first model, the second model from mice containing human leukemia cell line to assess the power of miR-22 therapy. In both models, the use of miR-22 treatment has brought a prolonged survival time and delays the progression of cancer.

Further tests are needed to verify the possibility of treating acute myelogenous leukemia using nanoparticles carrying miR-22 before the start of clinical trials. In addition, researchers have suggested that the combination of this therapy and chemotherapy drugs should also be effective for the treatment of acute myelogenous leukemia.

See more: http://www.cusabio.com/Recombinant-Protein/Recombinant-Rattus-norvegicus-Rat-Lumican-11106399.html